Application of nafamostat mesylate in hyperbilirubinemia patients with hepatic failure treated by artificial liver support system
Objective To evaluate the efficacy and safety of nafamostat mesylate(NM)in hyperbilirubinemia patients with hepatic failure(HF)treated with artificial liver support system(ALSS).Methods A total of 54 HF patients who received ALSS in our hospital from September 2020 to March 2023 were selected,of which 28 were treated with NM anticoagulation and 26 were treated with low molecular weight heparin(LMWH).All patients received two treatments,each lasting 3 hours.Hemodialyzer coagulation,bleeding complications,adverse reactions,total bilirubin(TBil)reduction rate,30,90 days survival rate were observed and measured.Results There was no significant difference in blood flow rate between the two groups(P＞0.05).After treatment,there was no significant difference in the reduction rate of TBil in the NM group compared with the LMWH group[(60.43±6.29)％vs(61.27％±6.45)％,P＞0.05].There were no significant differences in dialyzer coagulation,red blood cell transfusion,hypotension,30,90 days survival rate and nausea and vomiting between the two groups(P＞0.05).There was no gastrointestinal bleeding in the NM group,and 4 cases in the LMWH group,the difference was statistically significant(P＜0.05).Conclusion Compared with LMWH,NM does not increase the risk of bleeding in HF patients undergoing ALSS,and is a safe and effective anticoagulant.
nafamostat mesylateartificial liver support systemhepatic failurehyperbilirubinemialow molecular weight heparinanticoagulant
NETL
NSTL
万方数据
